Showing results (51-60 of 82) with videos related to
Sort By:
Pageof 9
Lung Cancer (Amsterdam, Netherlands)|September 28, 2021
Clinical relevance of circulating activin A and follistatin in small cell lung cancerNandor Barany, Anita Rozsas, Zsolt Megyesfalvi, et al.Oncotarget|June 26, 2014
Apelin promotes lymphangiogenesis and lymph node metastasisJudit Berta, Mir Alireza Hoda, Viktoria Laszlo, et al.Lung Cancer (Amsterdam, Netherlands)|January 31, 2025
Diagnostic and prognostic relevance of inflammatory markers in surgically treated thymic epithelial tumors: An international multicenter studyEvelyn Megyesfalvi, Aron Ghimessy, Jonas Bauer, et al.Journal of Oncology|January 14, 2020
Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based ChemotherapySabrina Borchert, Pia-Maria Suckrau, Michael Wessolly, et al.Cancer Research|September 14, 2012
Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasisChristine Heinzle, Andrea Gsur, Monika Hunjadi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2015
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung AdenocarcinomaZoltan Lohinai, Mir Alireza Hoda, Katalin Fabian, et al.Journal of Molecular Medicine (Berlin, Germany)|December 13, 2018
The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesotheliomaViktoria Laszlo, Zsuzsanna Valko, Judit Ozsvar, et al.Scientific Reports|October 30, 2020
Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesotheliomaSabrina Borchert, Pia-Maria Suckrau, Robert F H Walter, et al.Thoracic Cancer|June 21, 2023
Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosisBerta Mosleh, Karin Schelch, Thomas Mohr, et al.Cancers|October 12, 2019
KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based ChemotherapyAron Kristof Ghimessy, Aron Gellert, Erzsebet Schlegl, et al.Pageof 9